Antibiotic Therapy: How long is long enough?
|
|
- Austen Jefferson
- 5 years ago
- Views:
Transcription
1 Antibiotic Therapy: How long is long enough? By: David Milstein, C.Ph., BS, MHSA CLINICAL & REGULATORY NEWS BY PHARMERICA Antibiotics are highly regarded as safe and effective, but as with all medications, there are risks associated with their use, from the development of allergies and Clostridium difficile infections to increased antibiotic resistance. The growing bacterial resistance to antibiotics has been making headlines in the news and medical journals recently. As a result, prescribers face mounting pressures to reduce the risks associated with antibiotic resistance, and they are consistently prescribing shorter treatment courses. However, it is important for the prescriber to provide a treatment course that will adequately treat and prevent relapse. Several decisions may influence the length of therapy for antibiotic utilization: Choice of agent. Antibiotics work in one of two ways: either they are bactericidal, which kill the bacteria, or bacteriostatic, which inhibit the growth of the bacteria. The decision about which type of antibiotic to use depends on the bacteria count and the type of bacteria. A high count or quickly reproducing bacteria may require the use of a bactericidal drug, while a lower bacteria count or slower reproducing bacteria may permit the use of a bacteriostatic drug. Antibiotic s ability to penetrate and remain at the site of infection. Antibiotics penetrate different tissues in the body at varying rates. The site of the infection and the antibiotic s ability continued on page 2 MAY/JUNE 2018
2 PHARMACY NEWS Antibiotic Therapy, cont. to reach that site will affect the concentration of antibiotic in the infected area, as well as the length of the time the antibiotic stays at the infected site. Resident s immune status and bacteria causing the infection. Residents without hemodynamic issues may potentially be treated with shorter courses of therapy. For example, simple community-acquired pneumonia (CAP) may be treated with as little as five days of therapy. But if the resident s condition is complicated by bacteremia, or severe sepsis, a longer course of therapy is required. Additionally, because of the use of antibiotics in the past, different bacteria may be more resistant to the standard antibiotic indicated for a particular infection and may require a longer length of therapy, higher dose, or the addition of a second antibiotic. Within a few days of beginning therapy, improvements in the resident s hemodynamic condition, white blood cell count, temperature, oxygenation, and sometimes x-ray findings should be seen. Rechecking cultures is not always needed once the resident has started therapy, except with bloodstream infections. In fact, acquiring unnecessary cultures should be avoided because a positive culture without signs or symptoms of infection could lead to treating colonized bacteria. Once the resident s clinical symptoms are resolved, prescribers should consider terminating therapy. Recent studies have shown that there were no adverse reactions or rebound pneumonia when ending therapy for CAP early after symptoms have resolved compared to a full course of therapy. Prescribers can also utilize two new methods to determine antibiotic response and the duration of therapy: C-reactive protein (CRP) and procalcitonin tests. The procalcitonin test is more specific to bacterial infections and has been shown to For more information on Antibiotic Therapy, contact your PharMerica Consultant Pharmacist. Antibiotic Stewardship Facility Program PharMerica s Model Antibiotic Stewardship Facility Program can help keep you compliant with new requirements. Contact your Account Manager or Consultant Pharmacist for more details. reduce antibiotic therapy by between 23% and 25%. As prescribers decide the appropriate antibiotic and length of treatment, they should consider the potential benefits to shorter durations of therapies if clinically appropriate to help reduce the risk for development of resistance. As more research is done on short duration therapy, it may eventually become the standard of care. 2 MAY/JUNE 2018
3 F-TAG FOCUS Practical Considerations for Managing PRN Psychoactive Medication Use in the LTC Setting By Shannon Caddell, PharmD How well is your facility managing PRN (as needed) psychoactive medication use? Phase II of the Centers for Medicare and Medicaid Services (CMS) Mega Rule went into effect on November 28, 2017, and as a result, facilities must have a defined process in place to prevent pharmacy-related F-tags on their next survey. Since the implementation occurred six months ago, it is important to understand how surveyors are addressing these issues so you know how to remain in compliance. With the new regulations, CMS implemented rules on PRN psychotropics (defined as any drug that affects brain activities associated with mental processes and behavior, including, but not limited to antidepressants, anti-anxiety, and sedative/hypnotics) as well as PRN antipsychotic medication use. PRN Psychotropics PRN psychotropics now have a 14- day limitation on the duration of the order with an option for extension if the prescriber documents the rationale in the medical record and indicates the duration on the PRN order. But how long can this duration be extended? Can it be indefinite? CMS answered this question in an FAQ document released in January Since the intent of the regulation is to address concerns about residents remaining on PRN medications for an inappropriate length of time, the FAQ states that inde inite does not meet the intent of the regulation and should not be used. Anecdotal reports from recent surveys suggest that 30 or 60 days as an extension time frame has been accepted by surveyors. It is imperative that the rationale for the duration and the designated extension time be documented in the clinical record. PRN Antipsychotic Medications PRN antipsychotic medications also have a 14-day limitation on each order, but with one important difference: this class of drug may not be extended beyond 14 days. If a prescriber wants to renew the order for another 14 days, he or she must perform an evaluation of the resident for the appropriateness of continuing the order a step clarified by CMS in the same January FAQ document. The required evaluation must include a direct examination of the resident by the prescriber and an assessment of their current condition and progress to determine if the PRN antipsychotic is still needed. A verbal or written report of the patient to the prescriber from nursing center staff does not constitute an evaluation. Surveyors will review the medical record as well as interview staff to assess compliance. continued on page MAY/JUNE 2018
4 F-TAG FOCUS Practical Considerations, cont. Tips for Compliance To comply with the new rules, here are some tactics you can implement. Identify all PRN psychotropics and antipsychotics that are ordered. PharMerica has developed reporting to assist in this task via our customer portal, ViewMasteRx, where you can subscribe to the Daily Psychotropic New Starts Report. This report highlights residents with a new psychotropic drug order during any specified time period, e.g., the previous day, previous week, etc. By reviewing this report on a daily basis, you can then view each new start to make sure that all appropriate documentation (duration, clinical rationale, evaluation, etc.) is noted in the clinical record. Beware the use of comfort packs in hospice patients. The CMS FAQ also addressed the use of PRN antipsychotics in hospice patients and their use for another purpose such as an antiemetic. No exception currently exists for these situations so the 14-day limitation is being strictly applied. As a result, it is important to be aware of the historical use of hospice comfort packs since, many times, the bundled orders include PRN Haldol or ABH gel (Ativan/Benadryl/Haldol). Be sure to work with your hospice provider to establish processes to only order those medications at the time they are needed rather than pre-emptively write orders based on hospice status alone. Remove medications after order expiration. An area of concern that has resulted in survey tags is leaving a medication in the cart after the order has expired. If an order for a PRN antipsychotic has elapsed 14 days but the medication remains in the cart, surveyors may cite a facility. To avoid a citation, facilities should add a PRN medication check to their internal cart check schedules and remove medications in a timely manner even if the prescriber has indicated they will come in to do an evaluation. Only return the medication to the cart after the prescriber completes the evaluation and writes a new order. Implement a PRN Psychoactive Order template. To ensure that all documentation is in place before an order is carried out, a PRN Psychoactive Order template can be utilized. The template should address each requirement of the regulation and include space for documentation as necessary. Only orders that have every field completed on the template should be submitted, which will greatly reduce the risk of having a non-compliant medication order. Your consultant pharmacist can assist with this template implementation. To access the CMS FAQ document and related changes to the guidance referenced above go to: cms.gov/medicare/provider-enrollment-and-certification/ GuidanceforLawsAndRegulations/Downloads/LTC-Survey- FAQs.pdf 4 MAY/JUNE 2018
5 CLINICAL CORNER Survey Preparedness By Jeff Herr, PharmD Preparing for survey can be challenging and anxiety-provoking. But following a few survey preparation suggestions can help you get ready. 1. P & P Manuals. Remember that most of the functions your nursing staff performs are regulated by your nursing center Policy & Procedure (P & P) manuals, including those on nursing, infusion and IV, Antibiotic Stewardship, and any others your facility has implemented. Therefore, every nurse needs to know where the P&P manuals are and be familiar with the content. At your next staff meeting, ask your nurses if they can identify the location of the P&P manuals. If they cannot, that is a critical issue. Also, make sure you discard older manuals so there are no conflicting P&Ps available for viewing. Lastly, the manuals must be signed by all interdisciplinary team members annually to signify approval. 2. Infection Prevention. Your facility should have an Infection Prevention program fully implemented and known by all staff. All levels of staff should be following the determined parameters set by your interdisciplinary team for identifying when a resident has an infection (e.g. McGeers Criteria) as well as when to call the prescriber and with what information. Prescribers should be knowledgeable of facility protocols and procedures. After 48 to 72 hours, when additional information, including microbiology, radiographic and clinical information, is available, stops should be in place for confirming the antibiotic is still warranted, and more importantly, that it is effective against the organism. All members of the team should be up to date on what data to document and who to give documentation to for statistical analysis and trending of antibiotic utilization and resistance. Antimicrobial use assessments and tracking should reflect statistics that are useful in your Antibiotic Stewardship quality assurance meetings. 3. Med Pass. A large part of your survey includes the med pass and med room/med cart audits. Your Pharmacist Consultant and Nurse Consultants can make sure your team is ready by performing med pass, med room and med cart audits. Nursing Consultants can also perform such tasks as MAR to Cart or three-way audits to ensure everything is correct from the initiation of the medication order all the way to the MAR and administration to the residents. Infection control techniques are critical in this area and your entire team should be knowledgeable of and practicing appropriate procedures at all times. If you need assistance, your Pharmacist Consultant or Nursing Consultant can partner with you in survey preparedness. continued on page MAY/JUNE 2018
6 CLINICAL CORNER Survey Preparedness, cont. 4. Psychotropics. Psychotropic medication use is highly scrutinized by the state. Staff should be knowledgeable of the most recent regulations, including the Centers for Medicare and Medicaid Services Mega Rule. You should maintain clear documentation from interdisciplinary team psych meetings and ensure your care plan addresses minimal dose reductions on all psychotropic medications at least quarterly. While psychotropic dose reductions are not necessarily required, their utilization must be reviewed, considered for reduction, and documented a practice that reflects patientcentered care. All indications need to be accurate, and all behavior and side effects in this class of drugs must be monitored and visible on the MAR. Informed consents need to be given and documented and appropriate labs and assessments need to be completed within the appropriate time period. the interdisciplinary team must be reviewed and responded to with appropriate action occurring in a timely manner. All recommendations that are declined by prescribers based on clinical judgment must include the rationale behind their decision with accompanying medical justification and/or risk versus benefit statements. Declined recommendations without rationale will frequently result in cited deficiencies. By taking these steps with the support of your Pharmacist Consultant, your facility will be better prepared for a stress-free survey. 5. Medication Appropriateness. Your Pharmacist Consultant constantly looks at all medications and their appropriateness in terms of dosing, diagnosis/indication, organ function, disease state, allergy information, necessary lab work and interactions with the resident s other medications. Medication recommendations from the Pharmacist Consultant made to nursing, prescribers and For more information on Survey Preparedness, contact your PharMerica Consultant Pharmacist. 6 MAY/JUNE 2018
7 MEDICATION SPOTLIGHT Medication Spotlight: TRELEGY ELLIPTA By Brian Garcia, PharmD For chronic obstructive pulmonary disease (COPD) patients, TRELEGY (fluticasone furoate, umeclidinium, vilanterol) is the first and only once-daily triple therapy treatment delivered in a single inhaler. TRELEGY is indicated for the maintenance treatment of COPD in patients who are on a fixed-dose combination of fluticasone and vilanterol for airflow obstruction and reducing exacerbations. It is also for patients in whom additional treatment of airflow obstruction is desired or for those already receiving umeclidinium and a fixed-dose combination of fluticasone and vilanterol. Triple Therapy TRELEGY combines an inhaled corticosteroid (ICS), long-acting beta2 adrenergic agonist (LABA), and long-acting muscarinic antagonist (LAMA) in one daily inhalation. It is available in the Ellipta delivery device, which is also used for Breo (ICS/LABA) and Incruse (LAMA) products. Patients should discontinue use of Breo and Incruse products the dose before initiating TRELEGY therapy. Guidelines recommend triple therapy with an ICS, LABA, and LAMA (the components in TRELEGY for group D patients, defined as those who have a high risk of exacerbations and airflow limitation and have more symptoms of COPD. COPD has two primary subtypes: 1. Emphysema: in which the air sacs of the lungs are damaged and enlarged, causing breathlessness. 2. Chronic Bronchitis: which is constant irritation and inflammation of the lining of the bronchial tubes. Administration TRELEGY is administered once daily, with no adjustments for renal or mild hepatic impairment. TRELEGY should be used with caution in patients with moderate to severe hepatic impairment, as systemic fluticasone exposure may be increased up to threefold. Patients should rinse their mouth out and spit after each use because of the risk of thrush associated with fluticasone. All LABA-containing products, including TRELEGY, have a Black Box Warning for asthmarelated death, and are NOT indicated for the treatment of asthma or the relief of acute bronchospasm. If a patient misses a dose of TRELEGY, and it is close to the next dose, they should skip the missed dose and not use two doses at the same time. Side Effects As components of TRELEGY are not commonly systemically absorbed, there are limited systemic side effects. Common side effects include higher risk of respiratory infections (<8%), including nasopharyngitis, upper respiratory tract infections, and pneumonia. Rare adverse events include cardiovascular abnormalities (< 2%), anaphylaxis (<1%), and angioedema (<1%). TRELEGY is only indicated for patients who have already been on Breo as dual therapy. The GOLD For more information on TRELEGY ELLIPTA, contact your PharMerica Consultant Pharmacist. 7 MAY/JUNE 2018
Full details and resource documents available:
Clinical & Regulatory News by Pharmerica Urinary Tract Infection (UTI) Second Most Common Cause of Hospital Readmission within 30 days UTIs are prevalent and account for up to 22% of infections in LTC,
More informationTRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder
TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Zahava Picado, PharmD PGY1 Pharmacy Practice Resident Central Texas Veterans Healthcare System Temple, TX October
More informationClinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: Last Review Date: 08.18
Clinical Policy: (Daliresp) Reference Number: CP.PMN.46 Effective Date: 11.01.11 Last Review Date: 08.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationPrescribing guidelines: Management of COPD in Primary Care
Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish
More informationCombination Beta2-Agonist/Corticosteroid Inhalers Policy Number: Last Review: Origination: Next Review: Policy When Policy Topic is covered:
Combina ation Beta2-Agonist/Corticosteroid Inhalers Policy Number: 5.01.572 Origination: 06/2014 Last Review: 07/2014 Next Review: 07/2015 Policy BCBSKC will provide coverage for the combination beta2-agonist/corticosteroid
More informationLead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984]
Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] 1 st Appraisal Committee meeting Background & Clinical Effectiveness John McMurray 11 th January 2016 For
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationClinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46. Line of Business: Medicaid
Clinical Policy: (Daliresp) Reference Number: CP.PMN.46 Effective Date: 11/11 Last Review Date: 08/17 Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASE INCIDENCE UP TO 380,000 PEOPLE IN IRELAND HSE FIGURES 110,000 DIAGNOSED AND 200,000 UNDIAGNOSED. AFFECTS MORE MEN THAN WOMEN BUT RATES ARE RISING 1500 DEATHS PER YEAR
More informationNHS Dumfries & Galloway Triple therapy in COPD patients over 16 years
Title of Project: NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate choice and use of inhaled
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationNew Product to Market: Trelegy Ellipta Magellan Health, Inc. All rights reserved.
Drug Review and The following tables list the Agenda items as well as the that are scheduled to be presented and reviewed at the March 15, 2018 meeting of the Pharmacy and Therapeutics Advisory Committee.
More informationPATIENT INFORMATION BREO ELLIPTA
PATIENT INFORMATION BREO ELLIPTA [BRE-oh e-lip-ta] (fluticasone furoate and vilanterol inhalation powder) for oral inhalation What is BREO ELLIPTA? BREO ELLIPTA combines an inhaled corticosteroid (ICS)
More informationDisclosure Statement. Epidemiological Data
EVALUATION OF THE MEDICATION UTILIZATION OF COPD PATIENTS AT THE MIAMI VA HEALTHCARE SYSTEM Simone Edgerton, PharmD. PGY 1 Pharmacy Resident Miami VA Healthcare System Miami, Florida Simone.edgerton2@va.gov
More informationApril 10 th, Bond Street, Toronto ON, M5B 1W8
Comprehensive Research Plan: Inhaled long-acting muscarinic antagonists (LAMAs; long-acting anticholinergics) for the treatment of chronic obstructive pulmonary disease (COPD) April 10 th, 2014 30 Bond
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP 3 Main Categories Inhaled Respiratory Drugs Binds to beta-2 receptors Relaxation of smooth muscles in the lung
More informationNew and Novel Medications for Respiratory Care
New and Novel Medications for Respiratory Care JASON MOORE, PHARM.D. BCCCP CLINICAL STAFF PHARMACIST STORMONT-VAIL HEALTH Objectives Quick overview of the newest FDA-approved repiratory-related medications
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationIf you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team
MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:
More informationPain Management and Opioid Use in the Elderly
Pain Management and Opioid Use in the Elderly By Jim Mooney, RPh CLINICAL & REGULATORY NEWS BY PHARMERICA JULY/AUG 2018 Pain is common in older adults and is associated with the increased prevalence of
More informationMedical Directive. Activation Date: April 24, 2013 Review due by: December 1, Medical Director: Date: December 1, 2017
Medical Directive Pre and Post Bronchodilator Spirometry Testing and Treatment Initiation Assigned Number: Activation Date: April 24, 2013 Review due by: December 1, 2019 23 Approval Signature & Date Medical
More informationKentucky Department for Medicaid Services Pharmacy and Therapeutics Advisory Committee Recommendations
Kentucky Department for Medicaid Services Pharmacy and March 15, 2018 The following chart provides a summary of the recommendations that were made by the Pharmacy and Therapeutics (P&T) Advisory Committee
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationPATIENT INFORMATION. ADVAIR DISKUS [AD vair DISK us] (fluticasone propionate and salmeterol inhalation powder) for oral inhalation
PATIENT INFORMATION ADVAIR DISKUS [AD vair DISK us] (fluticasone propionate and salmeterol inhalation powder) for oral inhalation What is ADVAIR DISKUS? ADVAIR DISKUS combines the inhaled corticosteroid
More informationTHE COPD PRESCRIBING TOOL
THE COPD PRESCRIBING TOOL Revised edition, 2017 www.bpac.org.nz/copd CLASSIFICATION The COPD prescribing tool This tool provides pharmacological treatment options for patients with COPD based on their
More informationInhaled Corticosteroids Drug Class Prior Authorization Protocol
Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationFriend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines
Friend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines Program Learning Objectives At the conclusion of the activity, participants should be able to: Have a basic understanding
More informationWirral COPD Prescribing Guidelines
Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed
More informationQUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol)
Carelirst. +.V Family of health care plans DRUG CLASS COMBINATIONS QUANTITY LIMIT CRITERIA LONG ACTING BETA2-ADRENERGIC AGONIST, ORAL INHALATION BRAND NAME (generic) LONG-ACTING BETA2-ADRENERGIC AGONISTS:
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Indacaterol/Glycopyrrolate (Utibron Neohaler) Reference Number: CP.PMN.147 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important
More informationA Breath of Fresh Air? An update of novel inhalers used for the treatment of asthma and COPD
A Breath of Fresh Air? An update of novel inhalers used for the treatment of asthma and COPD Chris Federico PharmD, BCACP RIPF Kimberly McDonough Spring Seminar May 4, 2016 Disclosure I have no actual
More informationThe only COPD Triple Therapy delivered in a single daily inhalation. 1 Improvement in quality of life vs. ICS/LABA. 2
The only COPD Triple Therapy delivered in a single daily inhalation. 1 Improvement in quality of life vs. ICS/LABA. 2 Trelegy Ellipta is indicated for maintenance treatment in adult patients with moderate-to-severe
More informationUPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
UPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE Radhika Shah, MD Erlanger Health System University of Tennessee College of Medicine Chattanooga Respiratory, Critical Care, and Sleep medicine No disclosures
More informationDrug Class Monograph
Drug Class Monograph Class: Inhaled Corticosteroids Drugs: Aerospan (flunisolide), Advair Diskus, Advair HFA (fluticasone/salmeterol), Alvesco (ciclesonide), Arnuity Ellipta (fluticasone furoate), Asmanex
More informationUtibron Neohaler. (indacaterol, glycopyrrolate) New Product Slideshow
Utibron Neohaler (indacaterol, glycopyrrolate) New Product Slideshow Introduction Brand name: Utibron Neohaler Generic name: Indacaterol, glycopyrrolate Pharmacological class: Long-acting beta2- agonist
More informationJOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES
JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam
More informationumeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline
umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline 07 November 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationSTRIVERDI RESPIMAT (olodaterol hcl) aerosol
STRIVERDI RESPIMAT (olodaterol hcl) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationCombination Beta2-Agonist/Corticosteroid Inhalers
Combination Beta2-Agonist/Corticosteroid Inhalers Policy Number: 5.01.572 Last Review: 7/2017 Origination: 6/2014 Next Review: 7/2018 LoB: ACA Policy Blue Cross and Blue Shield of Kansas City (Blue KC)
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP October 23, 2017 Learning Objectives Be able to list at least 3 major adverse effects of inhaled medications
More informationInhaled Corticosteroids Drug Class Prior Authorization Protocol
Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationAlgorithm for the use of inhaled therapies in COPD
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.PMN.69 Effective Date: 11/15 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory
More informationAlgorithm for the use of inhaled therapies in COPD Version 2 May 2017
Algorithm for the use of inhaled therapies in COPD This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments
More informationChanging Landscapes in COPD New Zealand Respiratory Conference
Changing Landscapes in COPD New Zealand Respiratory Conference Dr Robert Young BMedSc MBChB DPhil (Oxon) FRACP FRCP Associate Professor Consultant Physician Changing Landscapes in COPD: Summary 1. Overview
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION (FLUTICASONE FUROATE/VILANTEROL) (Breo Ellipta GlaxoSmithKline) Indication: Chronic Obstructive Pulmonary Disease Recommendation: The Canadian Drug Expert Committee (CDEC) recommends
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
Adverse Effects of Inhaled Medications A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP June 28, 2017 Drug Category Beta 2 agonists antagonists Adverse Effects
More informationCOPD COPD. C - Chronic O - Obstructive P - Pulmonary D - Disease OBJECTIVES
COPD C - Chronic O - Obstructive P - Pulmonary D - Disease 1 OBJECTIVES Following this presentation the participant should be able to demonstrate understanding of chronic lung disease by successful completion
More informationyour breathing problems worsen quickly. you use your rescue inhaler, but it does not relieve your breathing problems.
MEDICATION GUIDE ADVAIR DISKUS [ad vair disk us] (fluticasone propionate and salmeterol inhalation powder) for oral inhalation What is the most important information I should know about ADVAIR DISKUS?
More informationNational COPD Audit Programme
National COPD Audit Programme Planning for every breath National Chronic Obstructive Pulmonary Disease (COPD) Audit Programme: Primary care audit () 2015 17 Data analysis and methodology Section 4: Providing
More informationTHEOPHYLLINE WITH INHALED CORTICOSTEROIDS (TWICS) TRIAL SELF MANAGMENT / ACTION PLANS GENUAIR INHALERS: POTENTIAL SAFETY ISSUE
I S S U E 4 M A R C H / A R P I L 2 0 1 6 Endorsed December 2014 I N S I D E T H I S I S S U E : Theophylline with Inhaled Corticosteroids (TWICS) Trial Genuair Inhaler: Potential Safety Issue 1 Self Management
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE
A F O C A l p O I N T l E A r N I N g p r O g r A m m E CHRONIC OBSTRUCTIVE PULMONARY DISEASE S E C O N D E D I T I O N BOOK 1 September 2013 FP120/1 CENTRE FOR PHARMACY POSTGRADUATE EDUCATION About CPPE
More information2017 GOLD Report. Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017
2017 GOLD Report Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017 Lauren Munro; BSc(Pharm) Amanda Burns; BSc(Pharm) Pharmacy Residents The Moncton Hospital Objectives Explain
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationMedicines Management of Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)
More informationCOPD Management in LTC: Presented By: Jessica Denney RRT
COPD Management in LTC: Presented By: Jessica Denney RRT Sponsored by Z & D Medical Services, Diamond Sponsor Seizing Opportunities to Provide Individualized Treatment and Device Selection for your COPD
More informationPharmacist Objectives. Pulmonary Update. Outline. Technician Objectives. GOLD Guidelines. COPD Diagnosis 9/22/2017
Pharmacist Objectives Pulmonary Update Patty Marshik, PharmD Associate Professor University of New Mexico College of Pharmacy pmarshik@salud.unm.edu Discuss the new Global Initiative for Chronic Obstructive
More informationCARE OF THE ADULT COPD PATIENT
CARE OF THE ADULT COPD PATIENT Target Audience: The target audience for this clinical guideline is all MultiCare providers and staff including those associated with our Clinically Integrated Network. The
More informationSummary of the risk management plan (RMP) for Laventair (umeclidinium bromide and vilanterol)
EMA/258177/2014 Summary of the risk management plan (RMP) for Laventair (umeclidinium bromide and vilanterol) This is a summary of the risk management plan (RMP) for Laventair, which details the measures
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationTRELEGY ELLIPTA Fluticasone furoate/umeclidinium/vilanterol dry powder for oral inhalation
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION TRELEGY ELLIPTA Fluticasone furoate/umeclidinium/vilanterol dry powder for oral inhalation Read this leaflet carefully
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Seebri Neohaler) Reference Number: CP.CPA.150 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationKey features and changes to these four components of asthma care include:
Guidelines for the Diagnosis and Management of Asthma in Adults Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions regarding
More informationOutcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationCase Study Simplifying and streamlining COPD treatment
Case Study Simplifying and streamlining COPD treatment The production of this case study has been organised and sponsored by GlaxoSmithKline. The healthcare professional involved received no payment for
More informationCOPD RESOURCE PACK Section 5. Drug Treatment & Inhalers in Stable COPD
COPD RESOURCE PACK Section 5 Drug Treatment & Inhalers in Stable COPD In this section: 1. Links to Fife Formulary 2. Pharmacological Management of Stable COPD 3. How to use a Metered Dose Inhaler 4. How
More informationEndobronchial valve insertion to reduce lung volume in emphysema
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Endobronchial valve insertion to reduce lung volume in emphysema Emphysema is a chronic lung disease that
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationMEDICATION GUIDE ANORO ELLIPTA
MEDICATION GUIDE ANORO ELLIPTA [a-nor oh e-lip-ta] (umeclidinium and vilanterol inhalation powder) for oral inhalation What is the most important information I should know about ANORO ELLIPTA? ANORO ELLIPTA
More informationChronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines
Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Where appropriate the following should be offered before commencing inhaled treatment: Offer treatment and support to stop smoking. Smoking
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy f the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationA COPD medication delivery device option: an overview of the NEOHALER
A COPD medication delivery device option: an overview of the NEOHALER 2017 Sunovion Pharmaceuticals Inc. All rights reserved 9/17 RESP019-17 Indication and Boxed Warning INDICATION ARCAPTA NEOHALER (indacaterol)
More informationMEDICATION GUIDE. ADVAIR [ad vair] HFA 45/21 (fluticasone propionate 45 mcg and salmeterol 21 mcg) Inhalation Aerosol
MEDICATION GUIDE ADVAIR [ad vair] HFA 45/21 (fluticasone propionate 45 mcg and salmeterol 21 mcg) Inhalation Aerosol ADVAIR HFA 115/21 (fluticasone propionate 115 mcg and salmeterol 21 mcg) Inhalation
More informationCOPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health
COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or
More informationBridges to Excellence Chronic Obstructive Pulmonary Disease Care Recognition Program Guide
Bridges to Excellence Chronic Obstructive Pulmonary Disease Care Recognition Program Guide Altarum Bridges to Excellence 3520 Green Court, Suite 300 Ann Arbor, MI 48105 bte@altarum.org www.bridgestoexcellence.org
More informationInitial U.S. Approval: 2013
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use BREO ELLIPTA safely and effectively. See full prescribing information for BREO ELLIPTA. BREO ELLIPTA
More informationADASUVE (LOXAPINE) INHALATION POWDER. EDUCATION PROGRAM for HEALTHCARE PROFESSIONALS
ADASUVE (LOXAPINE) INHALATION POWDER EDUCATION PROGRAM for HEALTHCARE PROFESSIONALS August2017 December 2012 PMR-JUN-2017-0017 ADASUVE Risk Evaluation and Mitigation Strategy (REMS) Education Program Content
More informationWhat s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent
More informationDuquesne University Mylan School of Pharmacy
Duquesne University Mylan School of Pharmacy Course Title: Pharmacy in Long Term Care Academic Semester: Fall 2016 Course Number: PHPR 466 Credits: 3 Prerequisites: None Course Hours: Tuesday 6-9 pm Please
More informationCOPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms
COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and
More informationThe Respiratory System
130 20 The Respiratory System 1. Define important words in this chapter 2. Explain the structure and function of the respiratory system 3. Discuss changes in the respiratory system due to aging 4. Discuss
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationInforMing the PAthway of COPD Treatment 1
InforMing the PAthway of COPD Treatment 1 A landmark trial in over 10,000 symptomatic COPD patients who had experienced at least one exacerbation in the last 12 months 1 (fluticasone furoate/umeclidinium/vilanterol)
More informationBetter Living with Obstructive Pulmonary Disease A Patient Guide
Better Living with Obstructive Pulmonary Disease A Patient Guide Second Edition November 2012 Queensland Health a Better Living with Chronic Obstructive Pulmonary Disease A Patient Guide is a joint project
More informationCOPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor
COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial
More informationFrom the Front Lines AlixaRx Clinical Pharmacists Address Everyday Challenges in Long-Term Care
May 2015 Issue From the Front Lines AlixaRx Clinical Pharmacists Address Everyday Challenges in Long-Term Care Behavior Monitoring When is behavior monitoring required? In Long-term care, medications are
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Calverley P M A, Anzueto A R, Carter K, et
More informationInterventional procedures guidance Published: 20 December 2017 nice.org.uk/guidance/ipg600
Endobronchial valve insertion to reduce lung volume in emphysema Interventional procedures guidance Published: 20 December 2017 nice.org.uk/guidance/ipg600 Your responsibility This guidance represents
More informationCo. Durham & Darlington Respiratory Network COPD Treatment Guide
Co. Durham & Darlington Respiratory Network COPD Treatment Guide Age > 35, Productive cough, Breathless, Smoking Hx Spirometry (post-bronchodilator) COPD Advice Intensive smoking cessation support Vaccination
More informationIncruse Ellipta 55mcg (umeclidinium bromide) for the relief of symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD):
Incruse Ellipta 55mcg (umeclidinium bromide) for the relief of symptoms in adult patients with Chronic Obstructive Pulmonary Disease (COPD): An introduction for Clinical Commisioning Groups and Health
More information